BioCentury
ARTICLE | Politics & Policy

PhRMA's Ubl unveils agenda

March 11, 2016 3:21 AM UTC

PhRMA President and CEO Stephen Ubl outlined new policies for the organization that he said would "enhance the private market and address costs holistically." At the organization's annual meeting on Thursday, Ubl presented a four-point plan that included elements that aim to modernize the drug discovery process, promote value-driven care, inform consumers and address market distortions.

The industry group urged FDA to update its drug approval policies, suggesting that the agency increase its use of biomarker-based endpoints and patient-reported outcomes, and allow adaptive clinical trial design. PhRMA also said financial incentives such as tax credits could encourage manufacturers to enter generics markets. ...